Drug intelligence / Profile preview

NCP-CD47 siRNA

Development stage: Phase 1
Lead developer: West China Hospital of Sichuan University
Modality: Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Nanoparticles → Drug Delivery Systems
Administration: Intratumoral

Overview

NCP-CD47 siRNA is an investigational RNA interference (RNAi)-based therapeutic developed by West China Hospital for the treatment of advanced solid tumors. The drug consists of a small interfering RNA (siRNA) targeting CD47, an immune checkpoint molecule widely overexpressed on tumor cells that provides a 'don't eat me' signal to macrophages. This siRNA is encapsulated within a non-cationic peptide (NCP) nanocarrier designed for intratumoral delivery. By silencing CD47 expression in tumor cells, the drug aims to disrupt the SIRPα signaling pathway, thereby restoring immune recognition and promoting the phagocytosis of cancer cells by macrophages and dendritic cells. It is currently being evaluated in a Phase 1, single-arm, dose-escalation clinical trial to assess safety, tolerability, and preliminary antitumor activity in patients with advanced solid tumors refractory to second-line treatment.

Other names: non-cationic peptide-CD47 siRNA nanocomplex

Targets

CD47 (Cluster of Differentiation 47)

Beyond the preview

Go deeper on NCP-CD47 siRNA.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NCP-CD47 siRNA.

Explore the full profile